成纤维细胞生长因子23与慢性肾脏病患者心血管疾病相关性的研究进展

Research Progress of the Relationship between Fibroblast Growth Factor 23 and Cardiovascular Disease in Patients with Chronic Kidney Disease

心血管疾病(CVD)是慢性肾脏病(CKD)患者常见的并发症和首要致死病因。成纤维细胞生长因子-23(fibroblast growth factor 23,FGF-23)是一种新型调磷因子,与CKD患者钙磷代谢紊乱的发生有关,与血管钙化、心室肥厚、心力衰竭、动脉粥样硬化的进展和预后以及心血管事件的发生率和死亡风险密切相关,是CKD患者心血管事件的预测因子。目前临床上尚无确切方法降低CKD患者血清FGF-23的水平,FGF-23有望成为CKD患者新的治疗靶目标。

Cardiovascular disease （CVD） is the most common complication and prime cause of death of patients with chronic kidney disease （CKD） . Fibroblast growth factor 23 （FGF-23） , a new type of phosphatonins, has a relationship with the occurrence of CKD, and is involved in the disorder of calcium-phosphorus metabolism, vascular calcification, ventrieular hypertrophy, heart failure and atheroselerosis, and also closely relates to the incidence rate of cardiovascular accidence and risk of mortality, which could be the indenpendent predictor of CVD. There is not a clinically effective method to reduce serum FGF-23 level in patients with CKD. FGF-23 would be a new treatment target for CKD patients.